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Abstract
Background: A recent and provocative meta-analysis, based on few outcome events, suggested that
rosiglitazone increased cardiovascular mortality and myocardial infarction. However, results of meta-analyses of
trials with sparse events, often performed when examining uncommon adverse effects due to common therapies,
can vary substantially depending on methodologic decisions. The objective of this study was to assess the
robustness of the rosiglitazone results by using alternative reasonable methodologic approaches and by analyzing
additional related outcomes.
Findings: In duplicate and independently, we abstracted all myocardial and cerebrovascular ischemic events from
all randomized controlled trials listed on the manufacturer's web site meeting inclusion criteria of the original
meta-analysis (at least 24 weeks of rosiglitazone exposure in the intervention group and any control group
without rosiglitazone). We performed meta-analyses of these data under different methodologic conditions. An
unconfounded comparison that includes only trials (or arms of trials) in which medications apart from
rosiglitazone are identical suggests higher risks than previously reported, making even the risk of cardiovascular
death statistically significant. Alternatively, meta-analysis that includes all trials comparing a treatment arm
receiving rosiglitazone to any control arm without rosiglitazone (as in the original meta-analysis) but also including
trials with no events in both the rosiglitazone and control arms (not incorporated in the original meta-analysis),
shows adverse but non-statistically significant effects of rosiglitazone on myocardial infarction and cardiovascular
mortality. Rosiglitazone appears to have inconsistent effects on a wider range of cardiovascular outcomes. It
increases the risk of a broad range of myocardial ischemic events (not just myocardial infarction). However, its
effect on cerebrovascular ischemic events suggests benefit, although far from statistically significant.
Conclusion: We have shown that alternative reasonable methodological approaches to the rosiglitazone meta-
analysis can yield increased or decreased risks that are either statistically significant or not significant at the p =
0.05 level for both myocardial infarction and cardiovascular death. Completion of ongoing trials may help to
generate more accurate estimates of rosiglitazone's effect on cardiovascular outcomes. However, given that
almost all point estimates suggest harm rather than benefit and the availability of alternative agents, the use of
rosiglitazone may greatly decline prior to more definitive safety data being generated.
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A recent [1] and provocative [2-4] meta-analysis suggested
that rosiglitazone increased cardiovascular morbidity and
mortality. Given the popularity of this medication, the
elevated risks of myocardial infarction (MI) (Peto odds
ratio [OR] 1.43; 95% confidence interval [CI] 1.03–1.98;
p = 0.03) and cardiovascular death (OR 1.64; 95% CI
0.98–2.74; p = 0.06) had broad public health implica-
tions. When interim results are added from the subse-
quently published RECORD trial [5], a phase III trial
investigating cardiovascular outcomes, the effect on cardi-
ovascular death is not significant (OR 1.08; 95% CI 0.78–
1.51; p = 0.64) but the increased risk of MI remains (OR
1.35; 95% CI 1.04–1.75; p = 0.02). Other meta-analyses
conducted by rosiglitazone's manufacturer [6], the US
Food and Drug Administration [7], and the Cochrane
Collaboration [8], in addition to two additional inde-
pendent meta-analyses [9,10], supported these findings
[1].
Meta-analysts [1] and others [2] have highlighted limita-
tions, such as the short duration of many included trials
that were not designed to assess cardiovascular outcomes,
leading to potential ascertainment bias, in addition to
sparse outcome events [3]. Indeed, results of a meta-anal-
ysis of trials with sparse events can vary substantially
depending on methodologic and statistical decisions [11-
13]. The objective of this study was to assess the robust-
ness of the rosiglitazone results using alternative reasona-
ble methodologic approaches and analyzing additional
related outcomes. In particular, we examine four relevant
issues not evaluated in previous analyses: 1) the effect of
including only trials (or arms of trials) with an uncon-
founded comparison, in which medications apart from
rosiglitazone are identical in the arms being compared, 2)
the effect of using odds ratios, which can be biased when
events are infrequent and group sizes are imbalanced, 3)
the effect of including trials with no events in both groups,
which would reduce pooled estimates of rosglitazone's
effect, and 4) the effect of various definitions of ischemia
outcomes (to examine for consistency of effect).
Methods
All randomized controlled trials on the manufacturer's
website [14] meeting inclusion criteria (any control group
and at least 24 weeks of drug exposure) for the original
meta-analysis [1] were reviewed. Our aim was to abstract
data from the same database of clinical trials searched in
the original meta-analysis [1], in addition to adding
interim data from the RECORD trial published in
response to the original meta-analysis. In duplicate, we
selected trials from the database and abstracted data from
included trials.
From each included trial, we abstracted data (number of
patients in intervention and control arm with an outcome
event and total patients in each arm) on the outcomes of
myocardial infarction and cardiovascular death.  For the
outcome of myocardial ischemia, we included all the fol-
lowing events (each was reported in at least one trial):
myocardial infarction (154 patients), myocardial
ischemia (301 patients), new angina (44 patients), angina
(36 patients), aggravated angina (19 patients), unstable
angina (8 patients), cardiac chest pain (1 patient), coro-
nary artery insufficiency (2 patients), revascularization
(62 patients), coronary thrombosis (6 patients), coronary
artery stenosis (2 patients), coronary artery occlusion (2
patients), coronary artery disorder (15 patients), coronary
artery disease (7 patients), coronary artery atherosclerosis
(2 patients), coronary artery spasm (1 patient), and three
vessel disease (1 patient).  For the outcome of cerebrovas-
cular event we included all the following events (each was
reported in at least one trial):  stroke (64 patients), cere-
brovascular accident (5 patients), cerebral infarction (1
patient), cerebral embolism (1 patient), cerebrovascular
disorder (43 patients), transient ischemic attack (31
patients), cerebral ischemia (1 patient), vestibulobasilar
insufficiency (1 patient), and carotid stenosis (2 patients).
For both myocardial ischemia and cerebrovascular events,
trials did not specify which patients had more than one
event among those listed above.  Therefore, if a trial
reported outcome events in more than one category, in
our primary analysis we assumed that the number of
patients with an event was equal to the maximum number
of patients in any one category.  In a sensitivity analysis we
used the least conservative approach and assumed that
each adverse event occurred in a different patient; our
results did not change.
Interim data for RECORD, which was not included in the
manufacturer's website [14], was obtained from reference
5 (myocardial infarction and cardiovascular death) and
reference 7 (stroke: 29 strokes in 2220 rosiglitazone
patients and 38 strokes in 2227 control patients). Data on
other myocardial and cerebrovascular ischemic events
were not available for RECORD.
Binary effect measure meta-analyses were carried out
using standard equations and confirmed with Review
Manager 4.2 (Cochrane Collaboration, Oxford, England)
where possible. Odds ratios derived using exact statistical
methods were calculated with StatXact 8 (Cytel Inc, Cam-
bridge, MA, USA) and odds ratios derived using Bayesian
methods were calculated with WinBUGS 1.4.1 [available
at http://www.mrc-bsu.cam.ac.uk/bugs/]).Page 2 of 10
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Influence of Trial Selection Criteria
The original meta-analysis [1] included some randomized
controlled trials in which the intervention and control
groups did not differ only in the use of rosiglitazone.
Some trials compared rosiglitazone to active control, and
in several 3-arm trials, groups receiving rosiglitazone
alone and groups receiving rosiglitazone and other
hypoglycemic agents were combined into 1 treatment
group in the meta-analysis. (RECORD also compared ros-
iglitazone to active control.) In such trials, assessment of
the risk of rosiglitazone is confounded. Including only tri-
als (or arms of trials) in which medications apart from
rosiglitazone are identical should provide a more specific
estimate of rosiglitazone's effect. Such a meta-analysis
(Figure 1) suggests an even higher risk of MI (p = 0.01)
and cardiovascular death (p = 0.03).
Influence of Effect Measure
The overall event rates in the rosiglitazone trials, even
including RECORD, are extremely low (0.7% for MI and
0.4% for cardiovascular death). Simulation studies
[11,12] have shown that in such circumstances, com-
monly used pooled odds ratios using inverse variance or
Mantel-Haenszel methods are negatively biased, showing
reduced treatment effects. Indeed, analyses using these
methods show no statistically significant effects, with
most p-values ≥ 0.10 (Figure 2). Although the authors of
the original meta-analysis [1] used Peto OR to minimize
this bias, many trials had imbalanced group sizes. Simula-
tion [11,12] also suggests that even Peto OR may underes-
timate true effect sizes under these conditions [15]. Using
other odds ratio methods less prone to bias (such as Man-
tel-Haenszel methods employing continuity corrections
that minimize bias, exact statistical methods, and Baye-
sian methods with non-informative priors), the risk of
adverse events was similar (Figure 2), suggesting that Peto
OR is an acceptable effect measure for these data despite
important theoretical shortcomings.
Influence of the Exclusion of Trials with No Outcome 
Events
Regardless of the specific form of odds ratio, however, this
effect measure forces the exclusion of studies with zero
events in both the intervention and control arms [16].
This occurs because odds ratios from such studies become
undefined due to division by zero when standard meth-
ods are used [13]. In addition to the 42 trials in the origi-
nal meta-analysis [1], we identified an additional 12 trials
on the manufacturer's web site [14] meeting inclusion cri-
teria but with no myocardial infarctions (though some
listed other myocardial ischemic or cerebrovascular
events) and no deaths from cardiovascular causes in both
intervention and control arms. Evaluating all 54 trials, 16
trials with 4241 patients (30% of all trials; 14% of 30242
patients in all trials) recorded no myocardial infarctions
and 31 trials with 9801 patients (57% of trials; 32% of
30242 patients) recorded no cardiovascular deaths.
The inclusion of such zero total event trials would move
effect estimates closer to nil. In principle, including such
trials is possible for any effect measure [13], but standard
methods allow it only for risk difference (RD). Re-analysis
of the data from all 54 trials using Mantel-Haenszel RD,
which is less prone to bias than inverse variance RD in low
event rate situations [12], shows no significant increase in
myocardial infarction (p = 0.06) or cardiovascular death
(p = 0.16) (Figure 3). If one includes only trials (or arms
of trials) in which medications other than rosiglitazone
are identical, the risk difference for MI just retains signifi-
cance at the p = 0.05 level (Figure 3). The increased abso-
lute risk of MI of 0.21% (95% CI 0.01%–0.41%), if true,
implies a number needed to harm of 476 (95% CI 244–
10,000) patients.
Consistency of Effect across Related Outcomes and over 
Time
Clinicians and regulators grappling with the implications
of important but subtle distinctions in meta-analysis
methodology may look to corollary evidence to guide
decisions regarding rosiglitazone. One approach to exam-
ine the robustness and consistency of the myocardial inf-
arction results would be to analyze rosiglitazone's effect
on all events resulting from myocardial ischemia. Doing
so and using the same statistical methods also suggests
increased risk (Figure 3). A related approach would be to
examine whether rosiglitazone's effect is similar in differ-
ent vascular territories. When the same methods are used
for cerebrovascular ischemic events, there is no evidence
of harm and, in fact, some suggestion of benefit (Figure
3). Thus, there appears to be consistency of effect using
various definitions of cardiac morbidity, but a lack of con-
sistency between cardiac and cerebrovascular effects. This
difference may reflect unknown mechanisms of rosiglita-
zone's effects on different vascular territories (for exam-
ple, increased congestive heart failure may contribute to
increased myocardial ischemia with little effect on cere-
bral ischemia) or may simply highlight chance differences
in trial outcomes when absolute event rates are low.
Finally, assessment of longer-term outcomes may support
the interpretation of results based on short-term follow-
up data. A recent meta-analysis [9] including the 4 pub-
lished trials with at least 12 months of follow-up [5,17-
19] also reported a statistically significant increased risk of
MI (p = 0.02). However, compared to the original meta-
analysis [1], these authors [9] included slightly different
numbers of myocardial infarction events for each of the 3
trials [17-19] common to the two papers. If instead they
had used the same event inclusion criteria as the originalPage 3 of 10
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from RECORD [5], they would not have found a statisti-
cally significant effect of rosiglitazone on MI (p = 0.07)
(Figure 4).
Discussion
Inferences regarding rosiglitazone's effect on adverse car-
diovascular events, based on meta-analysis of available
randomized controlled trials studying primarily low-risk
patients for relatively short intervals, depend on selection
of trials and effect measure. We have demonstrated that
different reasonable methodological approaches can yield
increased or decreased risks that are either statistically sig-
nificant or not significant at the p = 0.05 level for both MI
and cardiovascular death. Overall, our new analyses sup-
port concerns regarding increased cardiovascular risks of
rosiglitazone. However, they also highlight the challenge
of attributing rare adverse events to a particular drug and
the importance of using sensitivity analyses when results
are of borderline statistical significance.
We examined four methodologic issues relevant to a
meta-analysis of rosiglitazone's effects that were not com-
pletely considered in previous meta-analyses [1,2,6-10].
First, we determined the overall unconfounded effect of
rosiglitazone by comparing groups differing only by ros-
iglitazone therapy and showed higher estimates of harm
that achieve statistical significance even for cardiovascular
death. Second, we used other less biased effect measures
for low event rate data and found similar effects. Third, we
explored consistency of effects across outcomes; using a
broader definition of myocardial ischemia events we also
found statistically significant harm, but we did not find an
increased risk of cerebrovascular events. Finally, we
included additional trials with no outcome events, an
approach which decreases the magnitude of treatment
effects, and found that all risk difference point estimates
for rosiglitazone still suggest harm rather than benefit,
although some p-values are not statistically significant.
Others [2] have also re-calculated inverse variance and
Mantel-Haenszel odds ratios by including zero total event
trials (using methods suggested by us [13]) and showed
reduced estimates of harm due to rosiglitazone. However,
their results [2] are likely strongly influenced by the bias
towards no effect exhibited by inverse variance and Man-
tel-Haenszel odds ratios when event rates are very low. In
contrast, our analyses including zero total event trials used
an effect measure that minimized this bias to evaluate the
impact of such trials for rosiglitazone.
Conclusion
In summary, our additional new analyses strengthen the
original results, which have been questioned because of
sparse outcome events and borderline statistical signifi-
cance [3]. Ideally, a large randomized trial adequately
powered to detect differences in infrequent cardiovascular
adverse events would be conducted, especially since
results from such trials often differ from meta-analyses of
smaller trials [20]. However, given the very small absolute
increase in event rates, such a trial would need to be
extremely large. Ongoing [5] and future clinical trials may
help to generate more accurate estimates of rosiglitazone's
effect on cardiovascular outcomes, but will need to study
higher-risk patients for longer time periods, as rosiglita-
zone is intended for life-long use. Unfortunately, ongoing
trials like RECORD may still be underpowered to provide
definitive data due to lower-than expected events rates
and other trial design issues [7].
Other related data support concerns about rosiglitazone's
effects. A population-based observational study [21],
despite also having relatively few events and a study
design more prone to confounding, also suggests
increased cardiovascular risk from rosiglitazone. In addi-
tion, another recent meta-analysis [22] without the same
statistical issues suggests that pioglitazone, the other com-
mercially available thiazolidinedione, is not associated
with increased cardiovascular morbidity. The statistical
issues discussed here are less important for the pioglita-
zone meta-analysis because the event rates are higher and
the proportion of zero event rate trials is probably lower
(the exact proportion of such trials, considering both
included and excluded trials in the denominator, cannot
be calculated from data available in the paper [22]). More-
Effects of Rosiglitazone on Myocardial Infarction (MI, panel A) and Cardiovascular (CV) Death (panel B)Figure 1 (see previ us page)
Effects of Rosiglitazone on Myocardial Infarction (MI, panel A) and Cardiovascular (CV) Death (panel B). This 
analysis includes only trials in which the sole difference between the intervention and control groups is rosiglitazone therapy. 
Compared to the original analysis [1], this excludes trials AVM100264, 49653/020, 49653/080, 49653/097, 49653/137, SB-
712753/009, and ADOPT; it also excludes RECORD. For the 3-armed trials (49653/079, 49653/093, and SB-712753/007 
[marked with an '*']), we include only the treatment and control arms differing by rosiglitazone alone. Trials are ordered and 
grouped as per Table 1 in the original meta-analysis [1]. Only trials with events are shown. Weight refers to the contribution of 
each study's odds ratio (OR) to the overall pooled OR. The center of the diamond indicates the pooled OR, and the width of 
the diamond reflects the size of the 95% confidence interval (CI). Abbreviations: CI – confidence interval; CV – cardiovascular; 
MI – myocardial infarction; n – number of patients with event in the intervention or control group; N – total number of 
patients in the intervention or control group; OR – odds ratio; RCT – randomised controlled trial.Page 5 of 10
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up of almost 3 years [23], which compared pioglitazone
to placebo, dominated the results. This trial almost dem-
onstrated a statistically significant benefit in the primary
endpoint that included all-cause mortality, non-fatal
myocardial infarction, and stroke, among others, on its
own. Thus, data from these related studies makes an ade-
quately powered trial simply to disprove harm difficult to
justify from both ethical (potential harm to patients) and
resource perspectives.
Given the growing population with type 2 diabetes and
their high prevalence of cardiovascular disease, the accu-
rate and reliable determination of any cardiovascular risks
and benefits has enormous public health implications.
However, because available clinical trial data for rosiglita-
zone do not suggest improved clinical outcomes and pos-
sible harm, and because alternative agents are available,
clinicians may simply stop prescribing rosiglitazone with-
out definitive safety conclusions ever being generated.
Although such a situation is not ideal, given the available
Effect of Rosiglitazone on Myocardial Infarction and Cardiovascular MortalityFigure 2
Effect of Rosiglitazone on Myocardial Infarction and Cardiovascular Mortality. For each adverse clinical outcome, 
the pooled effect of rosiglitazone in different trial groupings is expressed as odds ratios (OR) and 95% confidence intervals (CI) 
using different statistical methods. For the Bayesian OR, CI denotes credible interval. Statistical methods with "Potential Nega-
tive Bias" may show reduced treatment effects. (1) This analysis includes only trials in which the sole difference between the 
intervention and control groups is rosiglitazone therapy. Compared to the original analysis, this excludes trials AVM100264, 
49653/020, 49653/080, 49653/097, 49653/137, SB-712753/009, and ADOPT. It excludes one arm in each of the 3-armed trials 
49653/093, 49653/079, and SB-712753/007. It also excludes RECORD. (2) Peto Odds Ratios as reported by Nissen and Wolski 
[1]. (3) Inverse Variance (IV) Odds Ratios using standard 0.5 continuity corrections in trials with no events in one group 
(Review Manager Software using a Random Effects Model with no heterogeneity [I2 = 0]). (4) Mantel-Haenszel (MH) Odds 
Ratios using standard 0.5 continuity corrections (CC) in trials with no events in one group (Review Manager Software using a 
Fixed Effects Model). (5) Mantel-Haenszel (MH) Odds Ratios using treatment arm continuity corrections (CC) in trials with no 
events in one group as proposed by Sweeting et al [11] to minimize bias. (6) Mantel-Haenszel (MH) Odds Ratios using empiric 
continuity corrections (CC) in trials with no events in one group as proposed by Sweeting et al [11] to minimize bias. (7) Odds 
Ratios calculated using exact statistical methods with no requirement for continuity corrections (StatXact 8 [Cytel Inc, Cam-
bridge, MA, USA]). (8) Odds Ratios along with 95% credible intervals calculated using fixed effects Bayesian method and non-
informative prior distributions with no requirement for continuity corrections (WinBUGS 1.4.1 [available at http://www.mrc-
bsu.cam.ac.uk/bugs/]). Abbreviations: CC – continuity corrections; CI – Confidence or Credible Interval; I2 – I2 heterogeneity 
statistic; IV – inverse variance; MH – Mantel Haenszel; OR – Odds Ratio; RSG – rosiglitazone.Page 6 of 10
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unreasonable.
Abbreviations
CI: confidence interval; MI: myocardial infarction; OR:
odds ratio; RD: risk difference.
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Effect of Rosiglitazone on Adverse Clinical OutcomesFigure 3
Effect of Rosiglitazone on Adverse Clinical Outcomes. For each adverse clinical outcome, the pooled effect of rosiglita-
zone in different trial groupings is shown using Peto OR (which includes trials with events) and RD (which includes trials both 
with and without events).    The RD analysis includes trials with 24 or more weeks of drug exposure listed on the manufac-
turer’s web site (http://ctr.gsk.co.uk/Summary/rosiglitazone/studylist.asp) meeting the inclusion criteria of the original meta-
analysis [1]. In addition to trials included in the original meta-analysis [1], we also include 6 additional trials with an active con-
trol group  (BRL 49653/282, BRL 49653/369, BRL 49653/392, BRL 49653/207, BRL 49653/325, 49653/109), 5 additional trials 
comparing rosiglitazone to placebo (49653/044, 49653/096, BRL 49653/131, 49653/390, 49653/452), and one additional 4-
armed trial with some arms differing only by rosiglitazone therapy (SB-797620/004).  For myocardial ischemia and cerebrovas-
cular morbidity individual trials did not specify which patients had more than one adverse event.  Consequently,if there were 
events in more than one category, we took the most conservative approach that the least number of patients in a particular 
trial arm had all these adverse events.  Alternatively, using the least conservative approach by assuming that each adverse event 
occurred in a different patient, the cerebrovascular result did not significantly change and the p-value for the myocardial 
ischemia results decreased.    
(1) Nissen and Wolski refers to the original meta-analysis [1].  
(2) This analysis includes data from all trials in the original meta-analysis [1] in addition to the RECORD trial [5].  
(3) This analysis includes only trials in which the sole difference between the intervention and control groups is rosiglitazone 
therapy.  Compared to the original analysis, this excludes trials AVM100264, 49653/020, 49653/080, 49653/097, 49653/137, 
SB-712753/009, and ADOPT.  It excludes one arm in each of the 3-armed trials 49653/093, 49653/079, and SB-712753/007.  It 
also excludes RECORD.    
Abbreviations:  CI – confidence interval; N – number of trials included in each meta-analysis; OR – Odds Ratio; RD – Risk Dif-
ference; RSG – rosiglitazone.Page 7 of 10
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This report by Friedrich et al. utilizes various meta-analytic
techniques to measure the cardiovascular risk of rosiglita-
zone. Irrespective of the methodology used, the results are
the same. They report a similar increased risk of myocar-
dial infarction (and cardiovascular death-statistically sig-
nificant at times) as seen in our rigorous meta-analysis of
long term trials with rosiglitazone, which showed that ros-
iglitazone is associated with increased ischemic risk with
long term use in patients with type 2 diabetes as compared
to alternative therapies [9].
However, there are several challenges in measuring rare
but important adverse effects in randomized trials because
of incomplete reporting of outcomes and inconsistent
definitions. The short term trials may be inadequately
powered to detect long term adverse effects, and hence we
Effect of rosiglitazone on myocardial infarction (MI) in randomized controlled trials with at least 12 months of follow-upFigure 4
Effect of rosiglitazone on myocardial infarction (MI) in randomized controlled trials with at least 12 months of 
follow-up. Singh et al [9] included only "serious events" rather than "total events" for ADOPT [17], only events leading to 
hospitalization rather than all investigator-reported MIs for Dargie et al [19], and for the DREAM study [18] included an addi-
tional rosiglitazone patient reported to have an MI that was included in a recent presentation by the manufacturer to the Food 
and Drug Administration [7] but not included in the original publication. In contrast, Nissen and Wolski [1] included all MIs for 
ADOPT [17] and Dargie et al [19] and used the published values for DREAM [18]. While the decisions made by Singh et al [9] 
were reasonable, each increased the risk of MI for rosiglitazone relative to control and thus contributed to a statistically signif-
icant result (Panel A). Alternatively, using the same event inclusion decisions as Nissen and Wolski [1] and including only adju-
dicated events from the subsequently published RECORD trial [5], the increase in MI no longer retains significance at the p = 
0.05 level (Panel B). If one limits the analysis to the two long-term trials in which the intervention and control groups differ only 
by rosiglitazone therapy [18,19] the risk increases; however, again it loses its statistical significance when the data used by Singh 
et al (RR 2.27 [95%CI 1.06 to 4.87], p = 0.03) are replaced by those used by Nissen and Wolski (RR 1.83 [95%CI 0.88 to 3.81], 
p = 0.11). For this figure we have used the same effect measure as Singh et al [9] (Risk Ratio [RR]); the p-values are identical if 
Peto OR is used as the effect measure. Weight refers to the contribution of each study's RR to the overall pooled RR. The 
center of the diamond indicates the pooled RR, and the width of the diamond reflects the size of the 95% CI. Abbreviations: CI 
– confidence interval; I2 – I2 heterogeneity statistic; MI – myocardial infarction; n – number of patients with event in the inter-
vention or control group; N – total number of patients in the intervention or control group; OR – odds ratio; RR – risk ratio; 
Z – Z test statistic.Page 8 of 10
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of the published data, and consistently extracted similar
categories of events such as those requiring hospitaliza-
tion or classified as serious adverse events, irrespective of
whether adjudicated or not because different trials may
have different ways of adjudication [9]. The use of adjudi-
cated and non-adjudicated events may give different risk
estimates. We also provided sensitivity estimates based on
the adjudicated events which showed a similar increased
risk [9].
The inclusion of zero event trials as done by the authors
of this article is problematic as it is unclear if no events
were reported or whether events did not occur. Several of
these problems can be fixed by consistent reporting of
outcomes of all trials and methodological consensus on
how best to conduct meta-analysis on sparse events.
However the authors overemphasize the precise estimate
of the RRs and the corresponding P values, which are
likely to vary given the different inclusion and exclusion
criteria. More important than the absolute precisions of
risk, the consistency of effects across comparisons suggests
a higher cardiovascular risk with rosiglitazone compared
to placebo or active controls, despite the modest benefit in
glycemic control seen with rosiglitazone. Finally observa-
tional studies have also proved to be useful and shown
similar increased cardiovascular risk with rosiglitazone
[21,24].
Hence accurate estimates of cardiac risk on ongoing trials
are unlikely to change this general scientific consensus
recommendations by the American Diabetes Association
that " rosiglitazone be avoided in the treatment of type 2 dia-
betes [25]. Infact, one can argue that it would be unethical
to conduct such a trial, and expose patients to harm, to
measure the precise cardiovascular risk of rosiglitazone,
given the overwhelming existing evidence on the cardio-
vascular adverse effects of rosiglitazone [26,27]. Unfortu-
nately a drug used to treat type 2 diabetes, where 2/3rd of
deaths are due to cardiovascular death, should at the min-
imum be cardiac neutral, which is not the case with rosigl-
itazone which raises the risk of cardiovascular adverse
effects no matter what methodology is used.
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